Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 21, 2016; 22(43): 9586-9594
Published online Nov 21, 2016. doi: 10.3748/wjg.v22.i43.9586
Published online Nov 21, 2016. doi: 10.3748/wjg.v22.i43.9586
Ceruloplasmin, a reliable marker of fibrosis in chronic hepatitis B virus patients with normal or minimally raised alanine aminotransferase
Da-Wu Zeng, Jing Dong, Jia-Ji Jiang, Yue-Yong Zhu, Yu-Rui Liu, Liver Center, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, Fujian Province, China
Author contributions: Zeng DW, Zhu YY and Liu YR designed the research; Zeng DW performed the research; Dong J analyzed the data; Zeng DW wrote the paper; Dong J and Jiang JJ revised the paper.
Supported by Youth Foundation of the Health and Family Planning Commission of Fujian Province , No. 2014-1-55 .
Institutional review board statement: This study was reviewed and approved by the Institutional Board of The First Affiliated Hospital, Fujian Medical University.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymized clinical data that were obtained after each patient agreed to treatment by verbal consent. Individuals can not be identified according to the data presented.
Conflict-of-interest statement: There are no conflict-of-interests involved in the article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Yue-Yong Zhu, MD, Liver Center, The First Affiliated Hospital, Fujian Medical University, No. 20 Chazhong Road, Taijiang District, Fuzhou 350005, Fujian Province, China. ezhu066@sina.com
Telephone: +86-591-87981660 Fax: +86-591-83356180
Received: July 10, 2016
Peer-review started: July 13, 2016
First decision: August 22, 2016
Revised: September 18, 2016
Accepted: October 10, 2016
Article in press: October 10, 2016
Published online: November 21, 2016
Peer-review started: July 13, 2016
First decision: August 22, 2016
Revised: September 18, 2016
Accepted: October 10, 2016
Article in press: October 10, 2016
Published online: November 21, 2016
Core Tip
Core tip: To date, few non-invasive approaches have been developed to evaluate liver fibrosis and no studies have proposed measuring ceruloplasmin (CP) levels for predicting liver fibrosis in chronic hepatitis B (CHB) virus patients with normal or minimally raised alanine aminotransferase (ALT). This study showed CP was independently and negatively associated with liver fibrosis. Furthermore, a simple and accurate CG model was developed to predict significant liver fibrosis and cirrhosis in CHB patients with normal or mildly elevated ALT. This model may be a valuable tool to replace liver biopsy in this category of hepatitis B virus-infected patients.